GSK plc American Depositary Shares (Each representing two Ordinary Shares) - GSK STOCK NEWS

WuXi Biologics has signed a license agreement with GSK granting exclusive rights to one preclinical bi-specific T cell engaging antibody and options for three more. WuXi Biologics will receive an upfront payment of $40 million and could earn up to $1.46 billion from milestone payments. The agreement highlights GSK’s expansion into novel cancer therapies and validates WuXi's proprietary technology platforms. The CEO of WuXi emphasized the significance of this partnership in facilitating GSK's ability to develop potentially life-saving treatments for patients worldwide.

GSK plc (LSE/NYSE:GSK) announced 48-week data from the MOMENTUM phase III clinical trial for momelotinib, showing significant efficacy in myelofibrosis patients previously treated with JAK inhibitors. Key findings include a 97% Total Symptom Score (TSS) response and 90% transfusion independence at week 24, with an associated improvement in overall survival. These results underscore momelotinib's potential as a treatment option to alleviate symptoms of myelofibrosis and reduce transfusion needs. A New Drug Application is currently under FDA and EMA review.

GSK and IQVIA have launched Vaccine Track, a new platform to enhance data transparency regarding adult vaccinations in the US. This resource aims to address the decline in adult immunization rates, particularly among minority populations, which saw an 18% drop in overall claims for recommended vaccinations from 2019 to 2021. The platform provides quarterly updates and diverse trend analyses, supporting public health efforts to improve vaccination rates post-pandemic. The initiative emphasizes the importance of vaccination data and could significantly impact public health policy.

GSK has received FDA approval for Benlysta (belimumab), making it the first biologic treatment for children aged 5 to 17 with active lupus nephritis (LN). This approval expands Benlysta's indications in the U.S. to include both lupus and active LN in pediatric patients. Lupus nephritis can lead to severe kidney complications. The treatment focuses on preserving renal function while reducing toxicities associated with traditional therapies. GSK aims to enhance treatment options and outcomes for children facing this serious condition.

GSK has initiated shipping of its FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT influenza vaccines to US healthcare providers for the 2022-23 season, following FDA approval. The company aims to distribute over 50 million doses to support annual immunization efforts. Despite extensive public health campaigns, vaccination rates in the US remain consistent with previous seasons. GSK emphasizes the need for increased awareness, particularly in underserved communities. Both vaccines are approved for patients aged six months and older, aligning with CDC recommendations.

GSK has awarded the inaugural £70,000 grant (about $100,000) to the HealthTree Foundation for its "HealthTree Equity and Diversity for Multiple Myeloma Program." This initiative aims to address disparities in care for underserved communities and minority patients. The funding will support digital tools for education and outreach, including programs like "Black Myeloma Health" and "HealthTree for Mieloma Multiple" to enhance information access and community engagement. GSK emphasizes its commitment to innovation in the multiple myeloma community through this initiative.

GSK has received FDA approval for PRIORIX, a measles, mumps, and rubella (MMR) vaccine, aimed at individuals aged 12 months and older. This marks the vaccine's debut in the US market, where it adds to GSK's pediatric vaccine offerings, currently distributed in over 100 countries with more than 800 million doses. The FDA's approval comes in response to recent measles outbreaks and declining vaccination rates in children, emphasizing the need for additional vaccine options to protect against these highly-contagious diseases.

GlaxoSmithKline's TUMS®, America’s leading heartburn brand, has launched a new campaign titled 'Love Food Back', aimed at encouraging consumers to embrace their favorite foods without fear of heartburn. This campaign pivots from a decade-long focus on combating heartburn to celebrating food enjoyment. The strategy includes interactive elements, such as the TUMS® Cam Sweepstakes, and features engaging advertisements showcasing humorous relationships between consumers and food. The campaign aims to redefine the emotional association with food and heartburn relief.